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Available online 6 April 2016Objectives: Over 250 medical centers worldwide offer ketogenic diets to children with epilepsy; however, access
to these therapies has been extremely limited for adults until recent years. We examine our 5-year experience
creating and implementing a dedicated Adult Epilepsy Diet Center designed to provide adults with epilepsy
access to ketogenic diets.
Material and methods: Outpatients seen at the Johns Hopkins Adult Epilepsy Diet Center from August 2010 thru
September 2015 age 18 years and older were enrolled in a prospective open-label observational study. Patients
that also enrolled in ongoing clinical diet trials were excluded from this study. Participant demographics, diet
type, urine and/or serum ketones, laboratory studies, seizure frequency, diet duration, reason for discontinuing
diet therapy, and side effects were recorded. A subgroup analysis of participants that met International League
Against Epilepsy (ILAE) criteria for drug-resistant epilepsy (DRE) and were treated de novo with a Modiﬁed
Atkins Diet (MAD) was performed to compare outcomes with the current literature regarding efﬁcacy of other
antiseizure treatments for DRE.
Results: Two hundred and twenty-nine adults attended the Adult Epilepsy Diet Center, and 168 met inclusion
criteria. Two-thirds (n = 113, 67%) were women with an age range of 18–86 years at the initial visit. Thirty-
ﬁve participants (21%, n = 133) were already on a therapeutic diet while 79% (n = 133) were naïve to diet
therapy at the time of the initial visit. Diet-naïve participants were typically prescribed MAD (n = 130, 98%),
unless unable to intake adequate oral nutrition, inwhich case theywere prescribed KD (n= 1) or a combination
of oral MAD and ketogenic formula (n= 2). Twenty-nine of 130 (22%) participants prescribed MAD elected not
to start or were lost to follow-up, and 101 (78%) began MAD.
A subgroup analysis was performed on one hundred and six participants naïve to diet therapy that met Interna-
tional League Against Epilepsy criteria for DRE, were able to tolerate oral nutrition, and were prescribed a MAD.
Relative to the number of enrolled participants who had reliable follow-up results for a given duration (including
those that ultimately elected not to start or were later lost to follow-up), at 3 months, 36% of these participants
responded (≥50% seizure reduction) to diet therapy, and 16% were seizure-free. At 1 year, 30% responded, and
13% were seizure-free. At 4 years, 21% responded, and 7% were seizure-free.
Hyperlipidemiawas themost common side effect (occurring in 39% of screenedparticipants, including those on a
therapeutic diet prior to the initial visit). Weight loss was also common (occurring in 19% of all participants
treated with a ketogenic diet therapy) yet was often an intended effect.
Signiﬁcance: This study, the largest series of adults with epilepsy treated with ketogenic diet therapies to date,
provides evidence that ketogenic diets may be feasible, effective, and safe long-term in adults, although
long-term adherence was limited and further adequately controlled studies are necessary to determine the efﬁ-
cacy of ketogenic diets in the treatment of adults with epilepsy.
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Although ketogenic diets are widely implemented for children
(in over 250 medical centers worldwide) with drug-resistant epilepsy
(DRE) and certain electroclinical syndromes [1], few epilepsy centers
worldwide offer these therapies to adults [2,3]. New antiseizure drugs,
devices for neurostimulation, and epilepsy surgery continue to be uti-
lized for refractory epilepsy in the adult population. In addition, diet
Table 1
Johns Hopkins Adult Epilepsy Diet Center Modiﬁed Atkins Diet protocol.
Prediet
Nutrition evaluation
Height and weight, calculation of body mass index
Three-day food record to calculate prediet caloric intake
Food preferences/practices (ex. religious)/prior diets, allergies, intolerances, aversions
Laboratory evaluations
Comprehensive metabolic panel, complete blood count, fasting lipid proﬁle,
vitamin D
Antiepileptic drug levels (if applicable)
Urine calcium, creatinine, human chorionic gonadotropin (premenopausal woman)
Diagnostic studies
EEG/Epilepsy Monitoring Unit evaluation (if diagnosis is unclear)
MRI with epilepsy protocol (if applicable)
Screening for cardio- and cerebrovascular risk factors, history of nephrolithiasis
Prediet calendar of daily seizures, start and end of menses (premenopausal women)
Initiation
Diet prescription
20 g net carbohydrates per day (subtracting ﬁber) Modiﬁed Atkins Diet
Liberal fat intake to satiety
Daily multivitamin, calcium and vitamin D supplement (low carbohydrate
brand)
Maintain adequate hydration
Monitoring (documented on a calendar)
Seizures daily
Urine ketones daily until reaching 40 mg/dL, then biweekly
Weights weekly
Start and end of menses (premenopausal women)
Follow-up
Clinic visits at 3 and 6 months then annually
Monitoring
Seizure frequency
Urine ketones
Food records/compliance
BMI changes
Side effects
Laboratory evaluations (annual unless otherwise speciﬁed)
Comprehensive metabolic panel, complete blood count, fasting lipid proﬁle (at
3 months and more frequent if elevated)
Antiepileptic drug levels
Vitamin D, zinc, selenium levels, free and total carnitine levels
Diagnostic studies
Renal ultrasound (if nephrolithiasis suspected)
ECG (if history of heart disease)
Carotid ultrasound (if prolonged fasting lipid elevation)
Bone density scan (every 5 years, minimum)
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sic (4:1 ratio of fat to carbohydrates and protein grams combined) Keto-
genic Diet.
Recently, several circumstances have been identiﬁed in which
the Classic Ketogenic Diet (KD) and other ketogenic diet therapies
(Modiﬁed Atkins Diet (MAD) [4,5], Medium-Chain Triglyceride (MCT)
Diet [6], and the Low Glycemic Index Treatment (LGIT) [7,8]) may be
beneﬁcial for adults. First, children on ketogenic diets transitioning out
of pediatric neurology clinics require ongoing care by an adult neurolo-
gist and registered dietitian [9]. Second, many adults with DRE carry di-
agnoses of electroclinical syndromes for which diet treatments have
been shown to be effective in childhood such as Rett syndrome [10,
11], tuberous sclerosis complex [12], Lennox–Gastaut syndrome [13],
and juvenile myoclonic epilepsy [14,15]. Third, adults with drug-
resistant focal epilepsy who are surgical candidates but not ready to
pursue surgery and adultswho are not surgical candidatesmay be seek-
ing an alternative to trying additional antiseizure drugs. Fourth, many
adults wish to reduce antiseizure drugs because of side effects. Finally,
recent retrospective studies have shown potential beneﬁt of ketogenic
diets in adults with refractory and super-refractory status epilepticus
who may require long-term diet treatment after recovery, though pro-
spective randomized trials are needed [2,16,17].
Several case series and reviews suggest that the efﬁcacy of ketogenic
diets in adults with epilepsy is comparable with that in children
[2,3,18–31]. The largest retrospective study to date of the KD from 1930
reported results in 19 adolescents and 81 adults, including patients
with both drug-naïve and drug-resistant seizures, of which 56% “derived
beneﬁt” [31]. Amore recent prospective study of 12 adults treatedwith a
3:1 ratio ketogenic diet showed a response rate (≥50% seizure reduction)
of 44% at 4months [18]while another study of 9 adults reported comple-
tion of a 12-week diet treatment in only 2 participants; both of whom
had a greater than 50% seizure reduction [25]. One prospective study ex-
amining the efﬁcacy of theMAD in 30 adults showed that 47% achieved a
≥50% seizure reduction at one and three months and 33% at 6 months
[20], and another prospective study of 18 adults reported a 28%
responder rate at 6 months [22]. Despite these promising results with
regard to efﬁcacy, access to these diets remains limited worldwide,
and concerns persist regarding adherence in adults.
Because of increasing demand, we created a multidisciplinary Adult
Epilepsy Diet Center (AEDC) in 2010 in order to provide ketogenic diets
to adults with epilepsy. The purpose of this study was to determine
whether ketogenic diets are a feasible and efﬁcacious treatment option
when provided to adults as part of a multidisciplinary, outpatient clinic.
2. Methods and materials
Consecutive patients age 18 years and older seen in theAdult Epilepsy
Diet Center (AEDC) at Johns Hopkins Hospital from August 2010 thru
September 2015 and not eligible for ongoing clinical diet trials
(NCT01796574, NCT01834482, or NCT02426047) were enrolled in
this prospective, open-label, observational study. The study was
approved by the Johns Hopkins Institutional Review Board. Written
consent to participate in the study was obtained by all patients or a
legally authorized representative for patients not capable of providing
informed consent.
At scheduling, patients were mailed or e-mailed a packet of written
instructions including a tracking calendar and were asked to record
seizures daily (type and frequency) until the ﬁrst clinic visit (1 or more
months prior to the initial visit) to establish a baseline seizure frequency
as part of standard clinical care. Patients already on ketogenic diets at the
time of scheduling were also asked to record biweekly urine ketones
prior to the initial visit.
At the time of enrollment, participants were scheduled for a
60-minute new-patient clinic visit with an adult epileptologist [MCC],
followed by a one-on-one interview with a registered dietitian [BJH].
Medical records were reviewed, and participant interviews wereconducted to determine seizure characteristics. Electroencephalography
ﬁndings and neuroimaging were used to classify seizure types and
electroclinical syndromes [32]. Medical records were also reviewed for
any evidence of an underlyingmetabolic disorder thatmight be contrain-
dicated [33,34] as well as cardiovascular risk factors, history of diabetes,
nephrolithiasis, anorexia, pancreatitis, cholecystectomy, osteopenia/
osteoporosis, and orthostatic hypotension, and at-risk patients were
counseled regarding potential risks of exacerbation or recurrence.
Baseline vital signs and laboratory studies were obtained per the AEDC
protocol (Table 1).
Participants not already on a form of diet therapy at the time of the
ﬁrst visit and able to tolerate oral nutrition attended a group instruc-
tional session (typically 60–90 min) on how to begin and continue a
20 g per day net carbohydrate limit MAD per protocol (Table 1). In-
creased fat intake was encouraged, but a speciﬁc target number of fat
grams per daywas not prescribed. Participants were provided amanual
containing a summary of the materials presented in the teaching ses-
sion, recommended micronutrient supplements, shopping lists, sample
menus, potential side effects and management, recipes, websites, and
books for reference (Supplementary material).
Those participants who were unable to tolerate oral nutrition were
prescribed a formula-based 4:1 ratio KD. Participants aged 21 years or
younger were ﬁrst started on KD with admission to the Johns Hopkins
Pediatric Ketogenic Diet inpatient service (before establishing care in
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overnight fast from approximately midnight until 5:00 pm the
following day, followed by introduction of a 4:1 ratio ketogenic diet at
half estimated calorie needs for 1 day then increased to full calories.
Serum glucose levels were monitored every 8 h for the ﬁrst 24 h, and
urine ketone levels were collected everymorning of the hospitalization.
These participants followed up as an outpatient ﬁrst in the Pediatric
Ketogenic Diet Center then in the AEDC. Participants over age 21 years
were started on a KD as an outpatient by beginning at 1/3 estimated cal-
orie needs for 1 day, increasing to 2/3 for 1 day then to full calories. Pa-
tients receiving nutrition via the combination of enteral and oral feeding
were prescribed a diet consisting of an oral MAD combined with a 4:1
ratio KD to obtain adequate daily caloric intake.
All participants were provided a new tracking calendar and
instructed to track seizures daily, urine ketone levels daily until they
achieved moderate urinary ketosis (40 mg/dL) then biweekly, and
weights weekly. Participants were instructed not to change antiseizure
drugs during the ﬁrst month of treatment unless deemed medically
necessary and to inform the study team immediately if changes were
made.
Participants returned for 30-minute follow-up visits with the
neurologist and then 30-minute visits with the dietitian at a minimum
of 3 and 6 months, then annually depending on the diet prescribed,
diet duration, response to treatment, adherence, and side effects.
Follow-up investigations were consistent with those recommended in
prior studies [33] (Table 1).
Descriptive statistics were used to present baseline characteristic
and safety data. Participants who met International League Against
Epilepsy criteria for DRE [35], who were naïve to diet treatment at the
time of the initial visit, andwhowere prescribed a 20-gramnet carbohy-
drate limit per day MAD were examined further to determine overall
diet efﬁcacy. Participants were excluded from this subanalysis if they
could not reliably quantify seizure frequency or established care fewer
than 3months before data analysis. Given that this was an uncontrolled,
open-label observational study, a ﬁnal analysis was performed including
only those participantswith DRE and no antiseizure drug changes for the
duration of the study.
Participants were deﬁned as diet “responders” if they had ≥50% sei-
zure reduction from baseline and deﬁned as seizure-free if they had no
seizures from the time of initial visit to AEDC to follow-up for patients
seen less than 1 year or seizure-free for one year ormore for participants
followedmore than 1 year. Proportionswere calculated for all categorical
variables, and means or medians, standard deviations, and ranges or in-
terquartile ranges were calculated for all continuous variables.
3. Results
3.1. Participants
From August 2010 to October 2015, 229 patients were seen in the
Johns Hopkins Adult Epilepsy Diet Center and 226 agreed to participate
(Fig. 1). Only 105 (46%) of the consented participants were residents of
the state ofMaryland,where the Centerwas located, and 4 patients (2%)
traveled internationally to attend clinic. Fifty-eight participants (25%)
enrolled in one of three clinical trials (NCT01796574, NCT01834482,
or NCT02426047) examining the ketogenic diet for super-refractory
status epilepticus (n = 5), the value of a ketogenic diet formula in
combinationwith theMAD in refractory epilepsy (n=51), or the effec-
tiveness of medium chain triglycerides as an adjunct to the MAD in
catamenial epilepsy (n = 2) and were therefore excluded. Among
the remaining 168 participants (Fig. 1, Table 2), 67% were women
(n = 113), and the age range was 18 to 86 years (mean age 38 years,
SD ± 78). Nine participants were presented in prior publications
[9,14,27].
Diagnoses included focal or multifocal epilepsy (n = 110 (66% of
168)), genetic generalized epilepsy (n = 37 (22%); a subset of whomwere reported previously [14]), symptomatic generalized epilepsy
(n = 15 (9%)), seizures with both generalized and focal features (n = 4
(2%)), and focal and nonepileptic seizures (n=2 (1%); these participants
were able to differentiate and quantify these seizure types, conﬁrmed
with inpatient Epilepsy Monitoring Unit evaluation).
Thirty-ﬁve participants (21%) were already on diet therapies at the
time of the initial visit and not enrolled in ongoing clinical diet trials.
The majority (n = 23; 66%) had started a diet independently or
with the assistance of an outside neurologist and/or dietitian. Several
(n = 9; 26%) were transitioning from the Johns Hopkins Pediatric
Ketogenic Diet Center to the AEDC (including one patient with Glucose
Transporter Type 1Deﬁciency syndromewho began a 3:1 ratio classic ke-
togenic diet at age 6 years and transitioned to the AEDC at age 20 years),
and a subset has been reported in a prior study [9], and a small number
(n = 3; 8%) previously participated in a study of the Modiﬁed Atkins
[20,27] or ketogenic diet [36] and were seeking outpatient follow-up.
Among the 133 participants (79%) that were naïve to diet therapy at
the time of the initial visit, 2 (2%) had been on no antiseizure drugs and
were seeking diet therapy as an alternative to starting an antiseizure
drug, 12 (9%) had tried only one antiseizure drug (including 4 that were
onno antiseizure drugs at theﬁrst visit because of intolerable side effects),
and the remaining 119 participants (89%) had tried 2 ormore drugs. Nine
participants (7%), 7 of whom had previously tried two or more drugs,
were seizure-free and attended clinic with the desire to lower antiseizure
drug burden. Ultimately, 112 participants met ILAE criteria for DRE (2 or
more drugs tried appropriate for the participant's seizure type at ade-
quate doses with continued seizures) [35], and of these, 106 were able
to intake adequate oral nutrition, reliably quantify seizures, and have 3
or more months of follow-up.
3.2. Diet prescriptions
Of 35 participants on ketogenic diets at the time of the initial visit
(again, excluding participants enrolled in ongoing diet trials), 22 (63%)
were on a MAD, 9 (26%) were on a KD, 3 (8%) were on a combination
diet (2 on KD with medium chain triglyceride oil added and one on a
combination of an oral MAD and KD enterally), and 1 participant (3%)
had eliminated carbohydrates from her diet but was not following a
strict ketogenic diet.
One hundred and thirty-three participants were naïve to diet thera-
py at the initial visit, and 130 (98%) were able to take in oral nutrition
and were prescribed MAD. Two participants who were enterally and
orally fed were prescribed an oral MAD with 4:1 ketogenic liquid
supplements (KetoCal®, Nutricia) to be taken when they were not
able to take in oral nutrition (e.g., in the setting of frequent seizures or
excessive sedation). One enterally fed participant (no oral nutrition)
over the age of 21 years was prescribed a 4:1 ratio ketogenic diet
initiated as an outpatient per the AEDC protocol.
3.3. Efﬁcacy and adherence
3.3.1. Patients already on diet therapy at initial visit
Of the 35 participants thatwere on ketogenic diets prior to the initial
visit, 27 (77%) remained on diet therapy throughout the study
(combined diet duration including prior to and after the ﬁrst visit to
AEDC ranged from 4 months to 36 years, median 32 months). Six (22%)
had a ≥50% seizure reduction (saw additional beneﬁt) since the initial
visit but did not achieve seizure freedom, 15 participants (56%) are
seizure-free (including 12 (44%) that were seizure-free at the time of
the ﬁrst visit to AEDC), and 6 (17%) have seen no change in their seizure
frequency or less than 50% seizure reduction since the initial clinic visit.
Eight participants are no longer on a ketogenic diet. Half (n = 4) of
those that stopped did not feel that they had adequate beneﬁt and
stopped after 5 months, 9 months, 3 years, and 7 years of diet therapy,
two were lost to follow-up, one was successfully tapered off of a MAD
after 1 year of seizure freedom without seizure recurrence, and one
Fig. 1. Participant enrollment.
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arrest related to an underlying metabolic disorder) after 18 years on a
classic ketogenic diet.
3.3.2. Patients naïve to diet therapy
One hundred thirty-three participants were naïve to diet therapy at
the initial visit (Fig. 1). Three could not intake adequate oral nutrition.
Of 130 participants who were introduced to an oral MAD at the time of
the initial visit, 101 (78%) actually began MAD, and 29 (22%) elected not
to start or never followed up in clinic after the initial visit (Fig. 1). Of the
29 participants that elected not to start, 16 (55%) perceived the diet toTable 2
Patient demographic and clinical characteristics.
On-diet at ﬁrst visit
(n = 35)
Diet naïve
(n = 133)
Gender, female 19 (54%) 94 (71%)
Age, years mean (range) 40 (18–86) 32 (18–70)
Intellectual disability 13 (37%) 27 (20%)
Age, years mean at seizure onset (range) 17 (0–70) 18 (0–83)
# antiepileptic drugs tried, mean (range) 6 (0–17) 6 (0–18)
Seizure frequency per week, median (IQR) 1 (12) 1 (7)
Epilepsy classiﬁcation
Localization-related 24 (69%) 86 (65%)
Idiopathic generalized 6 (17%) 31 (23%)
Symptomatic generalized 5 (14%) 10 (8%)
Generalized and focal features 0 4 (3%)
Focal and PNES 0 2 (1%)
IQR = interquartile range; PNES = psychogenic nonepileptic seizures.be too difﬁcult to follow, 7 (24%) elected instead to pursue antiseizure
medication changes, and 6 (21%) were lost to follow-up.
At the time of analysis, 44 (44%) of the original 101 participants that
beganMAD remain on the diet. Of these, 17 (17%) had a ≥50% seizure re-
duction but did not achieve seizure freedom, and 22 (22%) became
seizure-free. Nine (9%) have seen no change in their seizure frequency
or less than 50% seizure reduction since the initial clinic visit, and 57
(56%) have stopped the MAD or were lost to follow-up (Fig. 1).
Thedietduration range for the44participants still onMADis2months
to 5 years (median 25 months, mean 28 months, SD ± 18 months), and
the 57 participants that stopped MAD did so between 2 days and
2years after starting (median3months,mean5months, SD±5months).
Thirty-one participants that stoppedMAD (54% of 57) did so by 3months
and 46 (81%) by 6 months. Reasons for stopping included restrictiveness
(n = 28; 49%), participants lost to follow-up (n = 10; 18%), inadequate
beneﬁt (n = 13; 23%, including 4 with increased seizures), side effects
(n= 5; 9%), and unrelated injury (n= 1; 2%). Over half (30 participants;
53%) that decided to stop MAD had a ≥50% seizure reduction when they
elected to stop, and 21% (12 participants) were seizure-free from the
time that they beganMAD(duration 2days to 23months,mean5months
(SD ± 7), median 2 months). Of the 12 seizure-free participants that
elected to stop MAD, 11 (92%) found the diet to be too restrictive, and 1
(8%) stopped after an unrelated ankle fracture.
One patient who received nutrition via gastrostomy tube and started
the KD as an outpatient remained on the diet throughout the study
with N50% seizure reduction. One patient prescribed a combination diet
stopped after 4 months because of inefﬁcacy, and the second participant
died of Sudden Unexplained Death in Epilepsy (SUDEP) 2 months after
initiation of treatment.
Table 4
Treatment response and adherence in patients with drug-resistant epilepsy started on the
Modiﬁed Atkins Diet with no increase in other antiseizure therapies during the study.
Clinic visit Stopped Worse or
no change
b50%
seizure reduction
≥50% seizure
reduction
Seizure-free
3 months
(n = 48)
21 (44%) 2 (4%) 8 (17%) 17 (35%) 7 (15%)
6 months
(n = 47)
27 (57%) 1 (2%) 6 (13%) 13 (28%) 8 (17%)
1 year
(n = 42)
29 (69%) 0 (0%) 2 (5%) 11 (26%) 7 (17%)
2 years
(n = 33)
25 (76%) 0 (0%) 1 (3%) 7 (21%) 4 (12%)
3 years
(n = 20)
16 (80%) 0 (0%) 0 (0%) 4 (20%) 2 (10%)
4 years
(n = 11)
10 (91%) 0 (0%) 0 (0%) 1 (9%) 1 (9%)
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with MAD
Over 5 years, 112 participants met ILAE criteria for drug-resistant
epilepsy, and 106 met all inclusion criteria for further subanalyses. Six
did not meet inclusion criteria for further analyses: three were unable
to take in oral nutrition as described in Section 3.3.2, two were not
able to reliably quantify seizure frequency, and 1 was seen within
3 months of data analysis. The average number of antiseizure drugs
tried was 7 (SD ± 3, median 6, range 2–18). Eighty-seven (82% of
106) elected to begin MAD, and 19 (18%) never started. Three partici-
pants (3%) provided initial feedback that they started MAD but subse-
quently did not follow up in clinic (i.e., 84 (79%) participants began
MAD and were seen one or more times in follow-up; see Fig. 1).
Thirty-three participants that began MAD and followed up at least
once (39%) remained on the diet for the duration of the study, and
61% (n = 51) elected to stop. Efﬁcacy and retention rates at 3 months,
6 months, and 1–5 years are included in Table 3 for those participants
that have been followed for the speciﬁed duration or longer. Response
rate (≥50% seizure reduction) was highest at 3 months at 36% (n = 38
of 106), with 16% (n = 17 of 106) of participants seizure-free from
the time of diet initiation. In those participants followed for 4 or more
years from the time of the initial visit, 21% responded (n = 6 of 29
followed 4 or more years), and 7% were seizure-free for 1 year or
more (n = 2 of 29).
Forty-eight (57%) of 84 participants with DRE that began MAD had
no antiseizure drug changes throughout the course of the treatment
(Table 4). Of these, 17 (35% of 48) responded to MAD, and 7 (15%) were
seizure-free at 3 months. One of the 11 (9%) participants that were seen
at least 4 years prior to data analysis (ﬁrst seen between August 2010
and October 2011) with DRE remained on MAD with no medication
changes and was seizure-free. Ten of these participants stopped MAD.
Seven (8%) of 84 participants with DRE who began MAD were
seizure-free (n = 4) or diet responders (n = 3) and elected to lower
antiseizure drugs while remaining on MAD without a resultant increase
in seizure frequency or severity. The remaining twenty-nine participants
(35%) made changes to their antiseizure treatments (either increase in
medication(s) or switch from one to another) during treatment.3.3.4. Combined efﬁcacy and adherence
Combined, 139 participants began (n=133; 130 prescribedMAD, 1
prescribed KD, 2 prescribed combination diets) or continued (n= 35; 7Table 3
Treatment response and adherence in patients with drug-resistant epilepsy started on the Mo
Clinic visit Never Started/No follow-up Stopped Worse or no c
3 months
(n = 106)
22 (21%) 25 (23%) 6 (6%)
6 months
(n = 105)a
22 (21%) 38 (36%) 1 (1%)
1 year
(n = 98)b
21 (21%) 44 (45%) 0 (0%)
2 years
(n = 80)c
15 (19%) 45 (56%) 0 (0%)
3 years
(n = 56)d
13 (23%) 32 (57%) 0 (0%)
4 years
(n = 29)e
7 (24%) 16 (55%) 0 (0%)
5 years
(n = 3)f
0 (0%) 1 (33%) 0 (0%)
a Duration of follow-up b6 months, n = 1.
b Duration of follow-up b1 year, n = 8.
c Duration of follow-up b2 years, n = 26.
d Duration of follow-up b3 years, n = 50.
e Duration of follow-up b4 years, n = 77.
f Duration of follow-up b5 years, n = 103.on KD, 2 transitioned from KD to MAD, 3 on combination diets, 1
transitioned from carbohydrate restriction to MAD) on a ketogenic
diet after an initial clinic visit (Fig. 1). The combined diet duration
ranged from 2 days to 36 years (mean 29 months (SD ± 57), median
9 months). Seventy-two (52%) remain on a ketogenic diet therapy as of
data analysis. The average diet duration for these participants that have
continued diet therapy is 45 months (range 2 months to 36 years, SD
70 months, median 28 months). Forty-one percent (57/139) have
responded to diet therapy, and 27% (37/139) became seizure-free.
Of the remaining 67 (48% of 139) participants that are no longer on
diet therapy, 52 (37%) elected to discontinue diet therapy (including 1
on KD, 1 on combination therapy, and 50 on MAD), 12 (9%) were lost
to follow-up (all on MAD), 2 died (1%; 1 on KD and 1 on combination
therapy), and 1 (1%) tapered off of MAD after being seizure-free for
1 year. Diet duration among patients that stopped diet therapy ranged
from 2 days to 18 years (mean diet duration 10 months (SD ± 28),
median 3 months).3.4. Safety
One or more side effects were reported or identiﬁed in 54 (39%) of
139 participants during the course of the treatment with a ketogenic
diet (Table 5). The most common side effects were weight loss
(decrease in BMI ≥ 1 kg/m2) which occurred in 19% of participantsdiﬁed Atkins Diet.
hange b50%
seizure reduction
≥50% seizure reduction Seizure-free
15 (14%) 38 (36%) 17 (16%)
12 (11%) 32 (31%) 15 (14%)
4 (4%) 29 (30%) 13 (13%)
4 (5%) 16 (20%) 6 (8%)
2 (4%) 9 (16%) 4 (7%)
0 (0%) 6 (21%) 2 (7%)
0 (0%) 2 (67%) 1 (33%)
Table 5
Side effects and adverse events in adults on ketogenic diets.
Side effect n (% of 139 patients treated
with ketogenic diet therapy
unless otherwise speciﬁed)
LDL ≥ 130 mg/dLa 27 (29%, n = 92)
Weight loss 27 (19%)
Total cholesterol ≥ 240 mg/dLa 18 (20%, n = 92)
Triglycerides ≥ 150 mg/dLa 7 (8%, n = 92)
Worse seizures 8 (6%)
Constipation 5 (4%)
Weight gain 3 (2%)
HDL b 40 mg/dL 2 (2%, n = 92)
Acne 2 (1%)
Amenorrhea 2 (1%)
Carnitine deﬁciency 2 (1%)
Fatigue 2 (1%)
Nausea/Vomiting 2 (1%)
Newly diagnosed nephrolithiasis 2 (1%)
Newly diagnosed osteopenia/osteoporosis 2 (1%)
Abdominal pain 1 (b1%)
Alopecia 1 (b1%)
Cholecystitis 1 (b1%)
Diarrhea 1 (b1%)
Ecchymosis 1 (b1%)
Halitosis 1 (b1%)
Leg cramps 1 (b1%)
Serious adverse events
Cardiac arrest 1 (b1%)
Sudden Unexplained Death in Epilepsy (SUDEP) 1 (b1%)
a When not elevated prior to ketogenic diet therapy and not corrected with continued
treatment.
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240mg/dL, and/or triglycerides ≥ 150mg/dL at most recent lab collection
and not seen prior to starting diet) in 36 (39%) of 92 participants inwhom
these laboratory results were available. The LDL became elevated in 27
(29% of 92), total cholesterol became elevated in 18 (20% of 92), and
triglycerides became elevated in 7 (8% of 92). The HDL decreased below
40 mg/dL in 2 participants (2% of 92). More advanced lipid analyses
have been presented in a prior publication in a subgroup of these par-
ticipants [37]. Other common side effects included increased seizures
(n = 8, 6%) and gastrointestinal complaints (n = 8 (6%); 5 with
constipation, 2 with nausea and/or vomiting, 1 with abdominal pain).
Weight loss was an intended or welcomed effect of the diet in 15 of 27
(56%) of the participants that lost weight on diet therapy. During the
study period, 8 participants (6% of 139) received renal ultrasounds or
abdominal CTs for symptoms concerning for nephrolithiasis, and 2
(25% of 8 that received a diagnostic study, 1% of 139 participants) were
diagnosed with nephrolithiasis. Two participants (1%) had a history of
nephrolithiasis prior to treatment without recurrence during the study.
Eleven participants (8% of 139) received a bone density scan during the
study period; 6 of whom had a history of osteopenia or osteoporosis
prior to diet initiation. Two participants (1% of the 139 participants and
18% of the 11 that received bone density scans) were newly diagnosed
with osteopenia or osteoporosis during the study period.
Regarding serious adverse events, one participant died of SUDEP
2 months after starting a MAD in combination with a ketogenic liquid
supplement. The patient was a 39-year-old womanwith a history of tu-
berous sclerosis complex, severe intellectual disability (nonverbal,
wheelchair bound), and 4–10 focal seizures per month prior to diet
initiation despite 4 antiseizure drugs and vagus nerve stimulation. A
review of medical records indicates that she had not reached urine or
serum ketosis at the time of death, and cause of death was deemed to
be “seizure-related activity.” Another participant experienced cardiac
arrest after 18 years of treatment with the KD. This patient was a 22-
year-old woman with mitochondrial complex I and III deﬁciencies
with spastic quadriplegic cerebral palsy, intellectual disability (nonver-
bal), and status-post Nissen fundoplication with gastrostomy tube.These adverse events were deemed unlikely to be related to the keto-
genic diet by the treating physicians. Formal autopsies were not
performed.
3.5. Tapering ketogenic diets
Eighteen participants (13% of 139 participants on a ketogenic diet
therapy) were seizure-free for 2 or more years while followed in the
AEDC. Two (2%) were on a KD prior to the initial visit to AEDC and
seizure-free on initial presentation, 6 (4%)were onMADprior to the ini-
tial visit and seizure-free on presentation, and 10 (7%) were started on
MAD de novo. When appropriate, these participants were asked if
theywished to be tapered off of their ketogenic diet if follow-up electro-
encephalography showed no epileptiform activity, and all elected to re-
main on the diet with continued follow-up. One participant initially on
KD for refractory status epilepticus transitioned toMAD once able to in-
take oral nutrition [36] and ultimately tapered off ofMAD after 1 year of
seizure freedom, without seizure recurrence.
When participants elected to stopMAD, a tapering schedulewas rec-
ommended consisting of increasing carbohydrates by 5 g every 3 days
until reaching 85 g per day and decreasing fat intake ad libitum, at
which time the participant could resume their pre-MAD diet. Four
(7%) participants that discontinued MAD (n = 57) noted an increase
in seizures during the taper and elected to restart MAD, with return to
their prior on-diet seizure frequency.
4. Discussion
To our knowledge, this represents the largest series to date prospec-
tively examining the safety, tolerability, and efﬁcacy of ketogenic diet
therapies for adult epilepsy. This study also provides a detailed descrip-
tion of a structured Adult Epilepsy Diet Center (AEDC) and its develop-
ment over 5 years. The majority of patients that attended the AEDC
were women, and ages ranged widely from 18 to 86 years at the initial
visit. Four-ﬁfths of patients had never tried a ketogenic diet prior to the
initial visit, and over half of patients traveled from out-of-state or inter-
nationally to attend clinic, suggesting that there is an unmet need for
this treatment option for adults with epilepsy.
Overall, over half of participants who began a ketogenic diet
remained on a diet throughout the study. Of all 139 participants that
began or continued diet therapy after the initial visit, 41% (57 of 139)
responded to diet therapy, and 27% (37 of 139) became seizure-free.
Prior prospective studies have shown comparable results in smaller co-
horts of adults at three and six months [18,20,22,24,27,28], but more
long-term efﬁcacy has not been previously studied in a large cohort.
For those speciﬁcally with DRE starting theMAD de novo, 16% (17 of
106) were seizure-free at 3 months, 13% (13 of 98) at 1 year, and 7% (2
of 29) at 4 years. A prior large study of patients with DRE reported a 4%
rate of seizure freedom for 1 or more years after starting a 3rd drug or
combination of drugs [38]. More recent antiseizure drug studies do
not typically follow patients over several years. These ﬁndings suggest
that head-to-head trials of ketogenic diets versus adjunctive antiseizure
drug therapy may be justiﬁed in adults with DRE.
Approximately half of patients (48% or 67 of 139) discontinued the
diet (n = 55, 39%) or were lost after initial follow-up (n = 12, 9%).
Cited reasons for discontinuation included restrictiveness (51%), inef-
fectiveness (33%), side effects (9%), unrelated injury or death (5%),
and diet tapering in the setting of seizure freedom without recurrence
(2%). The majority (n = 51 of 55, 93%) discontinued within 6 months
of establishing care. Among those beginning the MAD, the majority
that stopped did so within the ﬁrst 3 months of starting the diet.
Reasons for stopping included difﬁculty with compliance (cited as the
primary reason by nearly 50% of patients), insufﬁcient seizure control,
and side effects. Additional methods may improve compliance, includ-
ing scheduled telephone calls or electronic communicationwith the su-
pervising dietitian and use of Seizure Tracker®, KetoDietCalculator™, or
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treatment to prevent early drop out [27].
Hyperlipidemia was the most common side effect, which has been
reported in a subset of these patients and has been shown to reverse
spontaneously in the majority of patients within the ﬁrst year of
treatment [37]. Weight loss was often an intended secondary effect
and occurred in one-ﬁfth of patients. Side effects were the reported
reason for stopping the diet in less than 10% of patients while over
half reported restrictiveness as the primary reason.
There were several important limitations to this study. Participants
were typically highly motivated and self-referred and often had a
secondary goal of weight loss, which may explain the larger proportion
of female participants in the study. Participants that were eligible for
participation in other clinical diet trials that are ongoing (those with 4
or more seizures per month on average, catamenial epilepsy on MAD,
or a history of refractory status epilepticus treated with the ketogenic
diet) were excluded, whichmay have biased the overall sample further.
The study was uncontrolled and open-label, so the effects of changes in
antiseizure drugs and other changes likely impacted overall efﬁcacy
over time. Two participants had known comorbid nonepileptic events
that were clearly distinguishable from their epileptic seizures, but
their seizure reporting could potentially be inaccurate. Finally, reported
frequencies of detected side effects such as nephrolithiasis and
osteopenia or osteoporosis are likely low because only a small fraction
of participants received serial renal ultrasounds or bone density scans.
In conclusion, ketogenic diets may be safe and effective long-term
treatments for adult epilepsy and are a promising adjunctive treatment
for patients with drug-resistant epilepsy. The establishment of an Adult
Epilepsy Diet Center has proved valuable to our epilepsy group and has
helped improve an apparent unmet need. Despite overall seizure reduc-
tion and unlimited access to a registered dietitian and neurologist, diet
adherence rates were still low long-term, and methods to improve
compliance are necessary. Given that this was an observational study
with a heterogeneous group of patients and that the results could
have been due to placebo effect, further adequately controlled studies
are necessary to determine the efﬁcacy of ketogenic diets in the treat-
ment of adults with epilepsy.Acknowledgments
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